<?xml version='1.0' encoding='utf-8'?>
<document id="12731459"><sentence text="Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori." /><sentence text="Current regimens for the eradication of Helicobacter pylori consist of a proton pump inhibitor (PPI) plus one or two antibacterial agents, such as amoxicillin (AMPC), clarithromycin (CAM) or metronidazole (MNZ)"><entity charOffset="147-158" id="DDI-PubMed.12731459.s2.e0" text="amoxicillin" /><entity charOffset="160-164" id="DDI-PubMed.12731459.s2.e1" text="AMPC" /><entity charOffset="167-181" id="DDI-PubMed.12731459.s2.e2" text="clarithromycin" /><entity charOffset="183-186" id="DDI-PubMed.12731459.s2.e3" text="CAM" /><entity charOffset="191-204" id="DDI-PubMed.12731459.s2.e4" text="metronidazole" /><entity charOffset="206-209" id="DDI-PubMed.12731459.s2.e5" text="MNZ" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e0" e2="DDI-PubMed.12731459.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e0" e2="DDI-PubMed.12731459.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e0" e2="DDI-PubMed.12731459.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e0" e2="DDI-PubMed.12731459.s2.e3" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e0" e2="DDI-PubMed.12731459.s2.e4" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e0" e2="DDI-PubMed.12731459.s2.e5" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e1" e2="DDI-PubMed.12731459.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e1" e2="DDI-PubMed.12731459.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e1" e2="DDI-PubMed.12731459.s2.e3" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e1" e2="DDI-PubMed.12731459.s2.e4" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e1" e2="DDI-PubMed.12731459.s2.e5" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e2" e2="DDI-PubMed.12731459.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e2" e2="DDI-PubMed.12731459.s2.e3" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e2" e2="DDI-PubMed.12731459.s2.e4" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e2" e2="DDI-PubMed.12731459.s2.e5" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e3" e2="DDI-PubMed.12731459.s2.e3" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e3" e2="DDI-PubMed.12731459.s2.e4" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e3" e2="DDI-PubMed.12731459.s2.e5" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e4" e2="DDI-PubMed.12731459.s2.e4" /><pair ddi="false" e1="DDI-PubMed.12731459.s2.e4" e2="DDI-PubMed.12731459.s2.e5" /></sentence><sentence text=" PPIs are mainly metabolized by S-mephenytoin 4'-hydroxylase (CYP2C19) in the liver" /><sentence text=" The polymorphism of CYP2C19 is associated with the pharmacokinetics and pharmacodynamics of PPIs" /><sentence text=" Eradication rates by PPI-based therapies are also affected by this genotype, as well as bacterial resistance to antibiotics" /><sentence text=" An individualized treatment strategy based on CYP2C19-related pharmacogenetics or pharmacogenomics and bacterial resistance is expected to increase the cure rate of the initial treatment" /><sentence text=" It is also necessary to recognize that there is a possible drug-drug interaction between some of the drugs used in this treatment regimen" /><sentence text="" /></document>